Literature DB >> 22882132

Low-shear red blood cell oxygen transport effectiveness is adversely affected by transfusion and further worsened by deoxygenation in sickle cell disease patients on chronic transfusion therapy.

Jon Detterich1, Tamas Alexy, Miklos Rabai, Rosalinda Wenby, Ani Dongelyan, Thomas Coates, John Wood, Herbert Meiselman.   

Abstract

BACKGROUND: Simple chronic transfusion therapy (CTT) is a mainstay for stroke prophylaxis in sickle cell anemia, but its effects on hemodynamics are poorly characterized. Transfusion improves oxygen-carrying capacity, reducing demands for high cardiac output. While transfusion decreases factors associated with vasoocclusion, including percent hemoglobin (Hb)S, reticulocyte count, and circulating cell-free Hb, it increases blood viscosity, which reduces microvascular flow. The hematocrit-to-viscosity ratio (HVR) is an index of red blood cell oxygen transport effectiveness that varies with shear stress and balances the benefits of improved oxygen capacity to viscosity-mediated impairment of microvascular flow. We hypothesized that transfusion would improve HVR at high shear despite increased blood viscosity, but would decrease HVR at low shear. STUDY DESIGN AND METHODS: To test this hypothesis, we examined oxygenated and deoxygenated blood samples from 15 sickle cell patients on CTT immediately before transfusion and again 12 to 120 hours after transfusion.
RESULTS: Comparable changes in Hb, hematocrit (Hct), reticulocyte count, and HbS with transfusion were observed in all subjects. Viscosity, Hct, and high-shear HVR increased with transfusion while low-shear HVR decreased significantly.
CONCLUSION: Decreased low-shear HVR suggests impaired oxygen transport to low-flow regions and may explain why some complications of sickle cell anemia are ameliorated by CTT and others may be made worse.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882132      PMCID: PMC3510323          DOI: 10.1111/j.1537-2995.2012.03822.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  30 in total

Review 1.  Rheological effects of red blood cell aggregation in the venous network: a review of recent studies.

Authors:  J J Bishop; A S Popel; M Intaglietta; P C Johnson
Journal:  Biorheology       Date:  2001       Impact factor: 1.875

Review 2.  Information transfer in microvascular networks.

Authors:  Timothy W Secomb; Axel R Pries
Journal:  Microcirculation       Date:  2002-10       Impact factor: 2.628

3.  Effect of aggregation and shear rate on the dispersion of red blood cells flowing in venules.

Authors:  Jeffrey J Bishop; Aleksander S Popel; Marcos Intaglietta; Paul C Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

4.  Blood transfusion in sickle cell disease: a cautionary tale.

Authors:  Graham Serjeant
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

Review 5.  Blood rheology and hemodynamics.

Authors:  Oguz K Baskurt; Herbert J Meiselman
Journal:  Semin Thromb Hemost       Date:  2003-10       Impact factor: 4.180

Review 6.  Rheology of the microcirculation.

Authors:  A R Pries; T W Secomb
Journal:  Clin Hemorheol Microcirc       Date:  2003       Impact factor: 2.375

Review 7.  Managing sickle cell disease.

Authors:  Susan Claster; Elliott P Vichinsky
Journal:  BMJ       Date:  2003-11-15

Review 8.  Nonlinear cardiovascular regulation consequent to changes in blood viscosity.

Authors:  Beatriz Y Salazar Vázquez; Pedro Cabrales; Amy G Tsai; Marcos Intaglietta
Journal:  Clin Hemorheol Microcirc       Date:  2011       Impact factor: 2.375

9.  Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome.

Authors:  Samir K Ballas; Beatrice Files; Lori Luchtman-Jones; Lennette Benjamin; Paul Swerdlow; Lee Hilliard; Thomas Coates; Miguel Abboud; Slawomir Wojtowicz-Praga; J Michael Grindel
Journal:  Hemoglobin       Date:  2004-05       Impact factor: 0.849

Review 10.  Purified poloxamer 188 for sickle cell vaso-occlusive crisis.

Authors:  Winter J Gibbs; Tracy M Hagemann
Journal:  Ann Pharmacother       Date:  2003-12-30       Impact factor: 3.154

View more
  14 in total

1.  Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease.

Authors:  Jon A Detterich; Roberta M Kato; Miklos Rabai; Herbert J Meiselman; Thomas D Coates; John C Wood
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

2.  Influence of feeding hematocrit and perfusion pressure on hematocrit reduction (Fåhraeus effect) in an artificial microvascular network.

Authors:  Walter H Reinhart; Nathaniel Z Piety; Sergey S Shevkoplyas
Journal:  Microcirculation       Date:  2017-11       Impact factor: 2.628

3.  Understanding sickle cell brain drain.

Authors:  Monica L Hulbert; Andria L Ford
Journal:  Blood       Date:  2014-08-07       Impact factor: 22.113

4.  Optimal hematocrit in an artificial microvascular network.

Authors:  Nathaniel Z Piety; Walter H Reinhart; Julianne Stutz; Sergey S Shevkoplyas
Journal:  Transfusion       Date:  2017-07-05       Impact factor: 3.157

5.  Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy?

Authors:  Jon A Detterich
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

6.  Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups - revisiting this controversial concept after 16 years of additional evidence.

Authors:  Payal Shah; Silvie Suriany; Roberta Kato; Adam M Bush; Patjanaporn Chalacheva; Saranya Veluswamy; Christopher C Denton; Kelly Russell; Maha Khaleel; Henry J Forman; Michael C K Khoo; Richard Sposto; Thomas D Coates; John C Wood; Jon Detterich
Journal:  Am J Hematol       Date:  2020-10-12       Impact factor: 10.047

7.  Vascular Instability and Neurological Morbidity in Sickle Cell Disease: An Integrative Framework.

Authors:  Hanne Stotesbury; Jamie M Kawadler; Patrick W Hales; Dawn E Saunders; Christopher A Clark; Fenella J Kirkham
Journal:  Front Neurol       Date:  2019-08-13       Impact factor: 4.003

8.  Characterizing Intracranial Hemodynamics in Sickle Cell Anemia: Impact of Patient-Specific Viscosity.

Authors:  Sara B Keller; Jacob M Bumpus; J Christopher Gatenby; Elizabeth Yang; Adetola A Kassim; Carlton Dampier; John C Gore; Amanda K W Buck
Journal:  Cardiovasc Eng Technol       Date:  2021-07-20       Impact factor: 2.305

9.  Longxuetongluo Capsule Improves Erythrocyte Function against Lipid Peroxidation and Abnormal Hemorheological Parameters in High Fat Diet-Induced ApoE-/- Mice.

Authors:  Jiao Zheng; Binglin Liu; Qixing Lun; Weijuan Yao; Yunfang Zhao; Wei Xiao; Wenzhe Huang; Yonghua Wang; Jun Li; Pengfei Tu
Journal:  Oxid Med Cell Longev       Date:  2015-11-16       Impact factor: 6.543

10.  Decreased hematocrit-to-viscosity ratio and increased lactate dehydrogenase level in patients with sickle cell anemia and recurrent leg ulcers.

Authors:  Philippe Connes; Yann Lamarre; Marie-Dominique Hardy-Dessources; Nathalie Lemonne; Xavier Waltz; Danièle Mougenel; Martin Mukisi-Mukaza; Marie-Laure Lalanne-Mistrih; Vanessa Tarer; Benoit Tressières; Maryse Etienne-Julan; Marc Romana
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.